ALISO VIEJO, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced plans to participate in the upcoming 23rd Annual Needham Virtual Healthcare Conference.
RxSight’s management is scheduled to participate in a fireside chat on Wednesday, April 10, 2024, at 12:45 p.m. Pacific Time / 3:45 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation at: https://investors.rxsight.com/.
About RxSight, Inc.
RxSight, Inc. is an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery. The RxSight® Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens® (LAL®), RxSight Light Delivery Device (LDD™) and accessories, is the first and only commercially available intraocular lens (IOL) technology that can be adjusted after surgery, enabling doctors to customize and deliver high-quality vision to patients after cataract surgery. Additional information about RxSight can be found at www.rxsight.com.
Company Contact:
Shelley B. Thunen
Chief Financial Officer
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor Relations Contact:
Oliver Moravcevic
VP, Investor Relations
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$33.16 |
Daily Change: | -1.06 -3.10 |
Daily Volume: | 111,214 |
Market Cap: | US$1.340B |
November 07, 2024 August 05, 2024 May 06, 2024 |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB